It is a time of challenges and uncertainties for the global biopharma industry and with the start of the second Trump Administration in the US, the international trade environment looks set to change drastically.
In South Korea, domestic political turmoil as well as economic indicators such as a trend of continued low growth, a strong dollar versus the won and poor investment sentiment, are
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?